Abstract
Angiogenesis is the formation of new blood vessels from existing vessels. The formation of new vessels appears to be an early and fundamental process for the evolution of the inflammatory response in synovial joints affected by arthritis. The propagation of new vessels in the synovial membrane allows the invasion of this tissue over the intra-articular cartilage in an adherent fashion. This process appears to support the active infiltration of synovial membrane into cartilage and results in erosion and destruction of the cartilage. This process results in joint damage and ultimately in deformity, as the normal joint architecture and balance of tendons becomes disrupted. Angiogenesis may be assessed in vivo by direct visualization through the introduction of a needle arthroscope using local anesthesia, differential patterns of vascular morphology have been described in seropositive rheumatoid arthritis and seronegative arthritides such as psoriatic and reactive arthritis. At a microscopic level, angiogenesis may be examined in the tissue sections using immunohistochemistry or immunofluorescence. Endothelial cells may also be studied in vitro in culture to examine production of angiogenic growth factors, cell activation, migration, and tubule formation. Finally, synovial biopsy explants may be cultured ex vivo to provide a model simulating the intra-articular milieu.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Folkman, J. and D’Amore, P. A. (1996) Blood vessel formation: what is its molecular basis. Cell 87, 1153–1155.
Polverini, P. J. (1995) The pathophysiology of angiogenesis. Crit. Rev. Oral. Biol. Med. 6, 230–247.
Folkman, J. (1997) Angiogenesis and angiogenesis inhibition: an overview. EXS. 79, 1–8.
Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorogenesis. Cell 86, 353–364.
Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., and McEver, R. (1998) Endothelial Cells in Physiology and in the Pathophysiology of Vascular Disorders. Blood 91, 3527–3561.
Koch, A. E. (1998) Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 41, 951–962.
Thomas, K. A. (1996) Vascular endothelial growth factor: a potent and selective angiogenic agent. J. Biol. Chem. 271, 603–606.
Reuterdah, C., Tingstrom, A., Terracio, L., Keiko, F., Heldin, C. H., and Rubin, K. (1991) Characterization of platelet-derived growth factor-β receptor expressing cells in the vasculature of human rheumatoid synovium. J. Clin. Invest. 1991. 64, 321–329.
Feldman, M., Brennan, F. M., and Maini, R. N. (1996) Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397–440.
Goddard, D. H., Grossman, S. L., Williams, W. V., et al. (1992) Regulation of synovial cell growth: coexpression of transforming growth factor B and basic fibroblast growth factor by cultured synovial cells. Arthritis. Rheum. 35, 1296–1303.
Koch, A. E., Polverini, P. J., and Kundel, S. L. (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 258, 1798–1801.
Sgadari, C., Angiolillo, A. L., and Tosato, G. (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87, 3877–3882.
Dumont, D. J., Fong, G. H., Puri, M. C., Gradwohl, G., Alitalo, K., and Breitman, M. L. (1995) Vascularisation of the mouse embryo: a study of flk-1, tie and vascular endothelial growth factor expression during development. Dev Dyn. 203, 80–92.
Veale, D., Yanni, G., Rogers, S., Barnes, L., Bresnihan, B., and FitzGerald, O. (1993) Reduced synovial macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis compared to rheumatoid arthritis. Arthritis Rheum. 36, 893–900.
Reece, R., Canete, J., Parsons, W., Emery, P., and Veale, D. J. (1999) Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis. Rheum. 42, 1481–1485.
Canete, J. D., Pablos, J. L., Sanmarti R., et al. (2004) Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 50, 1636–1641.
Veale, D. J. (1999) The role of arthroscopy in early arthritis. Clin. Exp. Rheumatol. 17, 37–38.
Jones, S. M., Dixey, J., Hall, N. D., and McHugh, N. J. (1997) Expression of the cutaneous lymphocyte antigen and its counter-receptor E-selectin in the skin and joints of patients with psoriatic arthritis. Br. J. Rheumatol. 36, 748–757.
Braverman, I. M. and Yen, A. (1974) Microcirculation in psoriatic skin. J. Invest. Dermatol. 62, 493–502.
Hull, S., Goodfield, M., Wood, E. J., and Cunliffe, W. J. (1989) Active and Inactive Edges of Psoriatic plaques: Identification by tracing and Investigation by Laser-doppler flowmetry and immunocytochemical techniques. J. Invest. Dermatol. 92, 782–785.
Veale, D., Barnes, L., Rogers, S., and FitzGerald, O. (1995) Immunolocalisation of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br. J. Dermatol. 132, 32–38.
Griffiths, C. E. M., Voorhees, J. J., and Nickoloff, B. J. (1989) Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumour necrosis factor. J. Am. Acad. Dermatol. 20, 617–629.
Creamer, D., Jagger, R., Allen, M., Bicknell, R., and Barker, J. (1997) Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br. J. Dermatol. 137, 851–855.
Fearon, U., Griosios, K., Fraser, A., et al. (2003). Angiopoietins, growth factors, and vascular morphology in early arthritis. J. Rheumatol. 30, 260–268.
Kraan, M. C., Reece, R. J., Smeets, T. J., Veale, D. J., Emery, P., and Tak, P. P. (2002). Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis. Rheum. 46, 2034–2038.
Kraan, M. C., Versendaal. H., Jonker, M., et al. (1998). Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 41, 1481–1488.
Benjamin, L. E, Golijanin, D., Itin, A., Pode, D. and Keshet, E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165.
Amin, M. A, Volpert. O. V., Woods, J. M., Kumar, P., Harlow, L. A., and Koch, A. E. (2003) Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ. Res. 93, 321–329.
Taniguchi, N. and Gutteridge, J. M. (2000) Experimental Protocols for Reactive Oxygen and Nitrogen Species. Oxford University Press, London pp. 40–41.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Fearon, U., Veale, D.J. (2007). Angiogenesis in Arthritis. In: Cope, A.P. (eds) Arthritis Research. Methods in Molecular Medicine, vol 135. Humana Press. https://doi.org/10.1007/978-1-59745-401-8_22
Download citation
DOI: https://doi.org/10.1007/978-1-59745-401-8_22
Publisher Name: Humana Press
Print ISBN: 978-1-58829-344-2
Online ISBN: 978-1-59745-401-8
eBook Packages: Springer Protocols